Neurodegenerative Disorder Therapeutics Market Trends Report 2025 – For Business Development and Strategy Teams
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#How Has the Neurodegenerative Disorder Therapeutics Market Growth Performance Trended Historically, And What Lies Ahead?
The market for therapeutics for neurodegenerative disorders has seen a robust growth recently. It is predicted to expand from $18.53 billion in 2024 to $20.04 billion in 2025, progressing at a compound annual growth rate (CAGR) of 8.1%. The past growth in the market can be traced back to factors like an increasing aging population, a higher occurrence of neurodegenerative disorders, increased life expectancy, greater investments from pharmaceutical firms, and heightened awareness and advocacy initiatives.
What Is the Forecast for the Neurodegenerative Disorder Therapeutics Market Size Through 2029?
The market for therapeutic solutions for neurodegenerative disorders is forecasted to experience substantial growth in the coming years. The market is projected to reach a value of $28.33 billion by 2029, achieving a Compound Annual Growth Rate (CAGR) of 9.0%. This growth is set to be fueled by a number of factors such as the increasing demand for personalized and targeted therapies, the widespread availability of clinical trials, and an overall increase in healthcare expenditure. Notable developments predicted for this period include therapies that modify the course of the disease, non-drug-based interventions, the use of telemedicine and remote monitoring, technological advancements, precision therapies, digital health initiatives, and trials centered around specific biomarkers.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2818&type=smp
What are the Key Market Players in Neurodegenerative Disorder Therapeutics Market and How They’re Evolving?
Major companies operating in the neurodegenerative disorder therapeutics market include Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Neuro-Hitech Inc., Bayer Schering Pharma AG, Amarin Corporation PLC, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Yangtze River Pharmaceutical Group Co. Ltd., Chongqing Zein Pharmaceutical Co. Ltd., Eisai Co. Ltd., Bristol Myers Squibb Company, AB Science S.A., Amylyx Pharmaceuticals Inc., Genentech Inc., GenSight Biologics S.A., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.
What Are the Primary Growth Drivers in the Neurodegenerative Disorder Therapeutics Market?
The growth of the neurodegenerative disorder therapeutics market is being fuelled by a rising incidence of neurodegenerative disorders among the global populace. This increase is driven in part by the rise in the elderly population, which has a higher occurrence of these conditions. As per the World Population Prospects data, by 2024, we are looking at a jump in individuals over 60 years old to 2.1 billion by 2050, while those over the age of 80 will have grown threefold to 425 million. Furthermore, figures from the Alzheimer’s Association reveal that nearly 5.8 million US citizens are battling Alzheimer’s disease, with the forecast indicating a surge to approximately 14 million by 2050. Hence, with an escalating occurrence of neurodegenerative diseases in the older demographic, the need for neurodegenerative disorder therapeutics amplifies, prompting the progression of the market in this field.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=2818&type=smp
What Are the Leading Segments in the Global Neurodegenerative Disorder Therapeutics Industry?
The neurodegenerative disorder therapeutics market covered in this report is segmented –
1) By Indication Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types
2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types
3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Parkinson’s Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics
2) By Alzheimer’s Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies
3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids
4) By Huntington’s Disease: Tetrabenazine, Antipsychotic Medications
5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments
What Are the Key Market Trends in the Neurodegenerative Disorder Therapeutics Industry?
Firms dealing with therapeutic treatments for neurodegenerative disorders are forming various strategic alliances with both governmental and non-governmental entities in order to explore and establish new therapies for an array of neurodegenerative diseases. There is also a rise in cooperation among participants in the neurodegenerative disorders therapeutics sector to amplify their research and development capabilities, with a focus on creating innovative and more successful treatment options. In a specific example from July 2022, NRG Therapeutics, a UK-based company that specialises in therapeutic solutions, collaborated with Domainex, a UK-based drug discovery service. The aim of their partnership is to collectively develop unique small-molecule disease-altering medications that can effectively treat Parkinson’s disease, motor neuron disease (MND) and other severe chronic neurodegenerative conditions.
Access The Full Report Here:
What Is the Regional Outlook for the Neurodegenerative Disorder Therapeutics Market?
The countries covered in the neurodegenerative disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2818
This Report Delivers Insight On:
1. How big is the neurodegenerative disorder therapeutics market, and how is it changing globally?
2. Who are the major companies in the neurodegenerative disorder therapeutics market, and how are they performing?
3. What are the key opportunities and risks in the neurodegenerative disorder therapeutics market right now?
4. Which products or customer segments are growing the most in the neurodegenerative disorder therapeutics market?
5. What factors are helping or slowing down the growth of the neurodegenerative disorder therapeutics market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
